Cargando…
Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial
BACKGROUND: High‐density lipoprotein (HDL) cholesterol has inverse association with cardiovascular disease. HDL possesses anti‐inflammatory properties in vitro, but it is unknown whether this may be protective in individuals with inflammation. METHODS AND RESULTS: The functional capacity of HDL to i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660788/ https://www.ncbi.nlm.nih.gov/pubmed/32799709 http://dx.doi.org/10.1161/JAHA.119.016507 |
_version_ | 1783609081869631488 |
---|---|
author | Ajala, Oluremi N. Demler, Olga V. Liu, Yanyan Farukhi, Zareen Adelman, Steven J. Collins, Heidi L. Ridker, Paul M Rader, Daniel J. Glynn, Robert J. Mora, Samia |
author_facet | Ajala, Oluremi N. Demler, Olga V. Liu, Yanyan Farukhi, Zareen Adelman, Steven J. Collins, Heidi L. Ridker, Paul M Rader, Daniel J. Glynn, Robert J. Mora, Samia |
author_sort | Ajala, Oluremi N. |
collection | PubMed |
description | BACKGROUND: High‐density lipoprotein (HDL) cholesterol has inverse association with cardiovascular disease. HDL possesses anti‐inflammatory properties in vitro, but it is unknown whether this may be protective in individuals with inflammation. METHODS AND RESULTS: The functional capacity of HDL to inhibit oxidation of oxidized low‐density lipoprotein (ie, the HDL inflammatory index; HII) was measured at baseline and 12 months after random allocation to rosuvastatin or placebo in a nested case‐control study of the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Evaluating Rosuvastatin) trial. There were 517 incident cases of cardiovascular disease and all‐cause mortality compared to 517 age‐ and sex‐matched controls. Multivariable conditional logistic regression was used to examine associations of HII with events. Median baseline HII was 0.54 (interquartile range, 0.50–0.59). Twelve months of rosuvastatin decreased HII by a mean of 5.3% (95% CI, −8.9% to −1.7%; P=0.005) versus 1.3% (95% CI, −6.5% to 4.0%; P=0.63) with placebo (P=0.22 for between‐group difference). HII had a nonlinear relationship with incident events. Compared with the reference group (HII 0.5–1.0) with the lowest event rates, participants with baseline HII ≤0.5 had significantly increased risk of cardiovascular disease/mortality (adjusted hazard ratio, 1.53; 95% CI, 1.06–2.21; P=0.02). Furthermore, there was significant (P=0.002) interaction for HDL particle number with HII, such that having more HDL particles was associated with decreased risk only when HDL was anti‐inflammatory. CONCLUSIONS: In JUPITER participants recruited on the basis of chronic inflammation, HII was associated with incident cardiovascular disease/mortality, with an optimal anti‐inflammatory HII range between 0.5 and 1.0. This nonlinear relationship of anti‐inflammatory HDL function with risk may account in part for the HDL paradox. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00239681. |
format | Online Article Text |
id | pubmed-7660788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76607882020-11-17 Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial Ajala, Oluremi N. Demler, Olga V. Liu, Yanyan Farukhi, Zareen Adelman, Steven J. Collins, Heidi L. Ridker, Paul M Rader, Daniel J. Glynn, Robert J. Mora, Samia J Am Heart Assoc Original Research BACKGROUND: High‐density lipoprotein (HDL) cholesterol has inverse association with cardiovascular disease. HDL possesses anti‐inflammatory properties in vitro, but it is unknown whether this may be protective in individuals with inflammation. METHODS AND RESULTS: The functional capacity of HDL to inhibit oxidation of oxidized low‐density lipoprotein (ie, the HDL inflammatory index; HII) was measured at baseline and 12 months after random allocation to rosuvastatin or placebo in a nested case‐control study of the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Evaluating Rosuvastatin) trial. There were 517 incident cases of cardiovascular disease and all‐cause mortality compared to 517 age‐ and sex‐matched controls. Multivariable conditional logistic regression was used to examine associations of HII with events. Median baseline HII was 0.54 (interquartile range, 0.50–0.59). Twelve months of rosuvastatin decreased HII by a mean of 5.3% (95% CI, −8.9% to −1.7%; P=0.005) versus 1.3% (95% CI, −6.5% to 4.0%; P=0.63) with placebo (P=0.22 for between‐group difference). HII had a nonlinear relationship with incident events. Compared with the reference group (HII 0.5–1.0) with the lowest event rates, participants with baseline HII ≤0.5 had significantly increased risk of cardiovascular disease/mortality (adjusted hazard ratio, 1.53; 95% CI, 1.06–2.21; P=0.02). Furthermore, there was significant (P=0.002) interaction for HDL particle number with HII, such that having more HDL particles was associated with decreased risk only when HDL was anti‐inflammatory. CONCLUSIONS: In JUPITER participants recruited on the basis of chronic inflammation, HII was associated with incident cardiovascular disease/mortality, with an optimal anti‐inflammatory HII range between 0.5 and 1.0. This nonlinear relationship of anti‐inflammatory HDL function with risk may account in part for the HDL paradox. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00239681. John Wiley and Sons Inc. 2020-08-15 /pmc/articles/PMC7660788/ /pubmed/32799709 http://dx.doi.org/10.1161/JAHA.119.016507 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Ajala, Oluremi N. Demler, Olga V. Liu, Yanyan Farukhi, Zareen Adelman, Steven J. Collins, Heidi L. Ridker, Paul M Rader, Daniel J. Glynn, Robert J. Mora, Samia Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial |
title | Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial |
title_full | Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial |
title_fullStr | Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial |
title_full_unstemmed | Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial |
title_short | Anti‐Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial |
title_sort | anti‐inflammatory hdl function, incident cardiovascular events, and mortality: a secondary analysis of the jupiter randomized clinical trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660788/ https://www.ncbi.nlm.nih.gov/pubmed/32799709 http://dx.doi.org/10.1161/JAHA.119.016507 |
work_keys_str_mv | AT ajalaoluremin antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT demlerolgav antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT liuyanyan antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT farukhizareen antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT adelmanstevenj antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT collinsheidil antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT ridkerpaulm antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT raderdanielj antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT glynnrobertj antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial AT morasamia antiinflammatoryhdlfunctionincidentcardiovasculareventsandmortalityasecondaryanalysisofthejupiterrandomizedclinicaltrial |